CureVac Announces Update to the Management Team

Chief Scientific Officer resigned

18-Jul-2023 - Germany
CureVac SE

Dr. Igor Splawski

CureVac N.V. announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, has stepped down effective July 14, 2023 to return to early-stage research in the United States. During the search for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’s unique mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.

“We are extremely grateful for Igor’s many contributions to CureVac’s research strategy and his vital role in bringing the company’s differentiated mRNA technology to the next level,” said Jean Stéphenne, Chairman of the Supervisory Board of CureVac. “I would like to sincerely thank him for his leadership and wish him all the best for his next steps.”

“Leading the development of CureVac’s mRNA technology and preclinical pipeline in these decisive years of strong growth and technology evolution has been a great privilege,” said Dr. Igor Splawski. “I truly enjoyed working with our brilliant scientists, who have pioneered some of the most significant breakthroughs in mRNA technology and continue to advance this exciting field. I would like to thank my CureVac colleagues for their trust and support.”

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances